Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Common Equity (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Common Equity for 7 consecutive years, with $181.2 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 40.41% to $181.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $181.2 million through Dec 2025, down 40.41% year-over-year, with the annual reading at $181.2 million for FY2025, 40.41% down from the prior year.
  • Common Equity for Q4 2025 was $181.2 million at Pliant Therapeutics, down from $200.3 million in the prior quarter.
  • The five-year high for Common Equity was $561.9 million in Q1 2023, with the low at $147.8 million in Q2 2022.
  • Average Common Equity over 5 years is $315.5 million, with a median of $284.1 million recorded in 2021.
  • The sharpest move saw Common Equity surged 507.98% in 2021, then crashed 43.95% in 2025.
  • Over 5 years, Common Equity stood at $199.1 million in 2021, then soared by 57.41% to $313.3 million in 2022, then skyrocketed by 51.14% to $473.6 million in 2023, then plummeted by 35.79% to $304.1 million in 2024, then tumbled by 40.41% to $181.2 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $181.2 million, $200.3 million, and $220.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.